Physician profile
Jonathan Berry
NPI 1346731932
$8,846.84
in general payments reported to CMS, 2019-2025
45 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $2,202 · 2023: $1,946 · 2024: $2,209 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,207 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,206.61 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,828.78 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $976.93 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $888.98 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $722.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $707.46 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $440.66 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $361.81 | 2021-2025 | Spravato |
| Axsome Therapeutics, INC. | $311.84 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $287.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $250.38 | 2022 | |
| Corium, LLC | $240.36 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.33 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $121.86 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.47 | 2022-2025 | |
| Dexcom, INC. | $115.29 | 2021-2025 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.